Management of Diabetic Foot Ulcers
The cornerstone of diabetic foot ulcer management is a five-pronged approach: aggressive offloading with non-removable devices, sharp debridement, infection control, vascular assessment with revascularization when indicated, and simple wound care with moist dressings—while avoiding expensive adjunctive therapies that lack strong evidence. 1
Core Management Principles
The International Working Group on the Diabetic Foot establishes five essential treatment pillars that must be addressed systematically 1:
1. Offloading (Most Critical Component)
For neuropathic plantar ulcers, use a non-removable knee-high offloading device—either a total contact cast or a removable walker rendered irremovable—as the preferred treatment. 1
- When non-removable devices are contraindicated, use removable offloading devices, though recognize these are significantly less effective due to poor patient compliance 2
- For non-plantar ulcers, consider shoe modifications, temporary footwear, toe-spacers, or orthoses 1
- Instruct patients to strictly limit standing and walking, using crutches if necessary 1
- Common pitfall: Relying on removable devices that patients inconsistently use is the most frequent management failure 2
2. Sharp Debridement
Perform scalpel debridement at initial presentation and repeat as frequently as clinically needed throughout treatment. 1, 3
- Remove all necrotic tissue, surrounding callus, foreign material, and debris 1, 3
- Sharp debridement removes colonizing bacteria, facilitates granulation tissue formation, and permits examination for deep tissue or bone involvement 3
- Inspect the ulcer frequently between debridement sessions 1
3. Infection Management
For superficial ulcers with mild infection 1:
- Cleanse and debride all necrotic tissue and surrounding callus 1
- Start empiric oral antibiotics targeting S. aureus and streptococci (cephalexin, flucloxacillin, or clindamycin) 1, 3
- Obtain wound cultures from the debrided base to guide antibiotic adjustment 3
For deep or limb-threatening infections (moderate to severe) 1:
- Urgently evaluate for surgical intervention to remove necrotic tissue, including infected bone, and drain abscesses 1
- Assess for peripheral arterial disease; if present, consider urgent revascularization 1
- Initiate empiric parenteral broad-spectrum antibiotics covering gram-positive, gram-negative, and anaerobic bacteria 1
- Adjust antibiotics based on clinical response and culture results 1
4. Vascular Assessment and Revascularization
If ankle pressure is <50 mmHg or ankle-brachial index (ABI) <0.5, obtain urgent vascular imaging and consider revascularization. 1
- Consider revascularization if toe pressure <30 mmHg or TcpO₂ <25 mmHg 1
- When an ulcer shows no signs of healing within 6 weeks despite optimal management, consider revascularization regardless of perfusion test results 1
- Before contemplating major (above-ankle) amputation, first consider revascularization options 1
- The goal is to restore direct flow to at least one foot artery, preferably the artery supplying the wound's anatomical region 1
- Important caveat: Pharmacological treatments to improve perfusion have not been proven beneficial 1
5. Local Wound Care
Clean the wound regularly with water or saline and maintain a moist wound environment using sterile, inert protective dressings. 1
- Select dressings to control excess exudation while maintaining moisture 1
- For exudative or purulent wounds, use alginates or foams to absorb drainage 3
- Change dressings based on wound characteristics—heavily exudating ulcers require frequent changes to prevent skin maceration 4
- Do not use footbaths where feet are soaked, as they induce skin maceration 1
Adjunctive Therapies: Limited Evidence
Therapies to Consider (Conditional Recommendations)
- Negative pressure wound therapy: Consider only for post-operative wounds; effectiveness and cost-effectiveness remain unestablished for non-surgical ulcers 1, 2
- Hyperbaric oxygen therapy: Consider for poorly healing wounds after standard care has failed; may increase healing incidence and improve long-term outcomes, though cost-effectiveness requires confirmation 1
Therapies NOT Recommended for Routine Use
The following lack sufficient evidence to justify routine use 1, 2:
- Biologically active products (collagen, growth factors, bioengineered tissue) 1, 2
- Silver-containing or other antimicrobial dressings 1
- Topical platelet-derived growth factor (becaplermin)—effectiveness remains unconfirmed despite FDA approval 1, 5
- Platelet suspension supernatants—early studies suggested benefit but no recent data 1
Critical note: The FDA label for becaplermin (REGRANEX) carries a warning about potential cancer risk, and retrospective studies show no mortality benefit, making its use difficult to justify 5
Treatment Monitoring and Adjustment
- Assess ulcer size every 1-2 weeks 5
- If the ulcer does not show approximately 30% reduction in area after 8-10 weeks, consider treatment failure and adjust management 5
- Adjust treatment if insufficient improvement is not observed after 2 weeks 2
Patient Education and Prevention
Instruct patients and caregivers on 1:
- Appropriate self-care and recognition of infection signs (fever, wound changes, worsening hyperglycemia) 1
- Daily foot inspection to prevent ulcers on the contralateral foot during bed rest 1
- After healing, enroll in an integrated foot-care program with lifelong observation, professional foot treatment, and therapeutic footwear 1
- The foot should never return to the same shoe that caused the ulcer 1
Cardiovascular Risk Reduction
Address systemic cardiovascular risk factors concurrently 1:
Multidisciplinary Team Structure
Organize care across three levels 1: